Spots Global Cancer Trial Database for antineoplastic agents
Every month we try and update this database with for antineoplastic agents cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma | NCT05964101 | Neoplasms Carcinoma, Squa... Antineoplastic ... | Nivolumab Injec... | 18 Years - 75 Years | The First Affiliated Hospital of Guangzhou Medical University | |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer (ENSEMBLE) | NCT05646511 | Locally Advance... | SCRT CAPOX CAPOXIRI | 18 Years - | National Cancer Center Hospital East | |
| A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | NCT04711252 | ER-Positive HER... | AZD9833 Anastrozole Anastrozole pla... AZD9833 placebo Palbociclib Luteinizing hor... | 18 Years - 130 Years | AstraZeneca | |
| Does a Nursing Intervention Improve Adherence to Oral Chemotherapies in the Outpatient Cancer Treatment Setting? | NCT02468245 | Antineoplastic ... | weekly telephon... usual care | 18 Years - | Bassett Healthcare | |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | NCT05874921 | Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Canc... Urothelial Carc... Carcinoma, Tran... Transitional Ce... | Jelmyto (mitomy... | 18 Years - | UroGen Pharma Ltd. | |
| Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) | NCT04776447 | Lung Diseases Carcinoma, Non-... Stage IIIA Non-... Stage IIIB Non-... Respiratory Tra... Carcinoma Bronc... Thoracic Neopla... | Carboplatin Placlitaxel Atezolizumab | 18 Years - 75 Years | Fundación GECP | |
| Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | NCT04144140 | Lymphoma Advanced Solid ... | E7766 | 18 Years - | Eisai Inc. | |
| Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer | NCT03923036 | Colorectal Canc... | Antineoplastic ... | 18 Years - | University Hospital, Caen | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| A Phase 1 Dose Escalation and Expansion Study of AK117 | NCT04728334 | Neoplasms Malig... | AK117 | 18 Years - 75 Years | Akeso | |
| Effects of Topical Sesame Oil in the Prevention of Peripheral Venous Catheter Phlebitis: Clinical Trial. | NCT06375850 | Phlebitis | Sesame oil Saline solution | 18 Years - | Hospital Universitario Marqués de Valdecilla | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors | NCT00264472 | Neoplasms | ADH300004 | 18 Years - | Adherex Technologies, Inc. | |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | NCT04485013 | Cancer | TTX-080 TTX-080 pembrolizumab cetuximab | 18 Years - | Tizona Therapeutics, Inc | |
| Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC | NCT05583188 | NSCLC | Aliya Pulsed El... Nivolumab plus ... Standard of car... Surgical Resect... | 18 Years - | Galvanize Therapeutics, Inc. | |
| Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy | NCT00300729 | Non-Small Cell ... | Celecoxib Placebo | 18 Years - | University Hospital, Linkoeping | |
| Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection | NCT04457297 | Colorectal Neop... Trifluridine an... Circulating Tum... | trifluridine an... Placebo | 20 Years - | National Cancer Center Hospital East | |
| A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days | NCT00002136 | Sarcoma, Kaposi HIV Infections | Tecogalan sodiu... | 18 Years - | NIH AIDS Clinical Trials Information Service | |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer | NCT05241340 | Urothelial Carc... | Sasanlimab Stereotactic Bo... Radical Cystect... | 18 Years - | The Methodist Hospital Research Institute | |
| Erbitux MEtastatic Colorectal Cancer Strategy Study | NCT02484833 | Antineoplastic ... | Cetuximab FOLFIRI | 18 Years - | Catholic University of the Sacred Heart | |
| Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors | NCT01204801 | Breast Cancer | Focused Microwa... Chemotherapy (c... | 18 Years - | Medifocus, Inc. | |
| Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients | NCT00002445 | Sarcoma, Kaposi HIV Infections | IM862 | 18 Years - | NIH AIDS Clinical Trials Information Service | |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | NCT03651375 | Sarcoma Fibrosarcoma Leiomyosarcoma Liposarcoma Myosarcoma Histiocytic Sar... Synovial Sarcom... Lymphangiosarco... Malignant Perip... Myxofibrosarcom... Myxoid Liposarc... Undifferentiate... Pleomorphic Lip... Undifferentiate... Dedifferentiate... Pleomorphic Rha... Malignant Trito... | Sequential chem... Hypofractionate... | 18 Years - 100 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | NCT01039948 | Carcinoma, Non-... Lung Neoplasms Lung Cancer Respiratory Tra... | AV-299 + gefiti... Gefitinib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma | NCT01345357 | Solid Tumors or... | CEP-9722 Gemcitabine Cisplatin | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma | NCT03150862 | Brain and Centr... | Pamiparib TMZ Radiation | 18 Years - | BeiGene | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma | NCT02010606 | Glioblastoma Glioblastoma Mu... Glioma Astrocytoma Brain Tumor | Dendritic cell ... Dendritic cell ... | 18 Years - | Cedars-Sinai Medical Center | |
| A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide | NCT03495921 | Ewing Sarcoma Ewing Family of... Ewing's Tumor M... Ewing's Sarcoma... Ewing's Tumor R... Rare Diseases Sarcoma Neoplasms, Conn... Neoplasms by Hi... Neoplasms, Bone... Neoplasms, Conn... Sarcoma, Ewing Neoplasms | Vigil Irinotecan Temozolomide | 2 Years - | Gradalis, Inc. | |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma | NCT05030077 | Urothelial Carc... Anlotinib Urogenital Neop... Cisplatin Carboplatin Gemcitabine Antineoplastic ... | Anlotinib Cisplatin Carboplatin Gemcitabine | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 | NCT04144140 | Lymphoma Advanced Solid ... | E7766 | 18 Years - | Eisai Inc. | |
| Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma | NCT00050440 | Endometrial Neo... Uterine Neoplas... Genital Neoplas... | Trabectedin Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | NCT05770544 | Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma | Entrectinib | - | Cancer Research UK | |
| Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | NCT06075849 | Solid Tumor, Ad... Solid Tumor Gastric Cancer Hepatocellular ... Metastatic Colo... Advanced Solid ... | PB101 | 19 Years - | Panolos Bioscience | |
| Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) | NCT01201811 | Myelodysplastic... | Azacitidine | 18 Years - | Celgene | |
| Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma | NCT02010606 | Glioblastoma Glioblastoma Mu... Glioma Astrocytoma Brain Tumor | Dendritic cell ... Dendritic cell ... | 18 Years - | Cedars-Sinai Medical Center | |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | NCT04676334 | Metastatic Cast... Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... Other Solid Tum... | Rucaparib | 18 Years - | pharmaand GmbH | |
| A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection | NCT03083743 | Non-small-cell ... | Recombinant hum... Placebo | 18 Years - 75 Years | Shanghai Gebaide Biotechnology Co., Ltd. | |
| Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy | NCT02300727 | Mucositis | Curcumin-MTD Mouthwash-stand... Curcumin | 18 Years - | Aurora BayCare Medical Center | |
| Anlotinib in Metastatic HER2 Negative Breast Cancer | NCT04002284 | Breast Neoplasm Antineoplastic ... Anlotinib | Anlotinib Hydro... | 18 Years - 75 Years | ChineseAMS | |
| An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer | NCT01397305 | Rectal Cancer | [6R] 5,10-methy... Pemetrexed | 18 Years - | Isofol Medical AB | |
| A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) | NCT02766699 | Glioblastoma Astrocytoma, Gr... | EGFR(V)-EDV-Dox | 18 Years - | Engeneic Pty Limited | |
| Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA) | NCT06409481 | Cardiovascular ... Cardiac Disease... Vascular Diseas... Cancer | Antineoplastic ... | 18 Years - 100 Years | The First Affiliated Hospital of Xinxiang Medical College | |
| A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors | NCT05315180 | Malignant Neopl... Metastatic Canc... | BPI-421286 | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. | |
| A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT02941601 | Locally Advance... Metastatic Squa... | Necitumumab Gemcitabine Carboplatin | 18 Years - | Eli Lilly and Company | |
| Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) | NCT02252159 | MPN (Myeloproli... | 18 Years - | Incyte Corporation | ||
| Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma | NCT00002226 | Sarcoma, Kaposi HIV Infections | SU5416 | 18 Years - | NIH AIDS Clinical Trials Information Service | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| Effects of Topical Sesame Oil in the Prevention of Peripheral Venous Catheter Phlebitis: Clinical Trial. | NCT06375850 | Phlebitis | Sesame oil Saline solution | 18 Years - | Hospital Universitario Marqués de Valdecilla | |
| Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer | NCT04163900 | Biliary Tract C... | NUC-1031 Gemcitabine Cisplatin | 18 Years - | NuCana plc | |
| A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction | NCT01273493 | Neoplasm Metast... Hepatic Insuffi... | Trabectedin Dexamethasone | 18 Years - 70 Years | Janssen Research & Development, LLC | |
| FLX475 in Combination With Ipilimumab in Advanced Melanoma | NCT04894994 | Advanced Melano... | FLX475 Ipilimumab | 18 Years - | RAPT Therapeutics, Inc. | |
| Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) | NCT02112656 | Hepatocellular ... | ThermoDox Dummy infusion | 18 Years - | Imunon | |
| Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | NCT03680521 | Clear Cell Rena... | Sitravatinib Nivolumab | 18 Years - | Mirati Therapeutics Inc. | |
| A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | NCT04104776 | Advanced Solid ... Diffuse Large B... Lymphoma, T-Cel... Mesothelioma, M... Prostatic Neopl... Endometrial Can... Ovarian Clear C... | CPI-0209 | 18 Years - | Constellation Pharmaceuticals | |
| Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT01289522 | Squamous Cell H... Recurrent or Me... | cetuximab IV Biopsies | 18 Years - 70 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer | NCT05388773 | Oropharynx Canc... | therapeutic con... laboratory biom... quality-of-life... intensity-modul... Cisplatin Carboplatin | 18 Years - | University of Pittsburgh | |
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| Study of ASTX029 in Subjects With Advanced Solid Tumors | NCT03520075 | Solid Tumor, Ad... | ASTX029 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma | NCT05964101 | Neoplasms Carcinoma, Squa... Antineoplastic ... | Nivolumab Injec... | 18 Years - 75 Years | The First Affiliated Hospital of Guangzhou Medical University | |
| Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors | NCT04669899 | Cancer | JTX-8064 pimivalimab | 18 Years - | Jounce Therapeutics, Inc. | |
| A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4 | NCT00002137 | Sarcoma, Kaposi HIV Infections | Tecogalan sodiu... | 18 Years - | NIH AIDS Clinical Trials Information Service | |
| Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | NCT01183949 | Multiple Myelom... | AT7519M Bortezomib | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | NCT05379985 | Non-small Cell ... Colorectal Canc... Pancreatic Duct... Advanced Solid ... | RMC-6236 | 18 Years - | Revolution Medicines, Inc. | |
| A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT02941601 | Locally Advance... Metastatic Squa... | Necitumumab Gemcitabine Carboplatin | 18 Years - | Eli Lilly and Company | |
| A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | NCT04981665 | Hepatocellular ... Adjuvant Therap... | Tislelizumab TACE | 18 Years - | Zhejiang University | |
| Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy | NCT01316458 | Prostatic Neopl... Genital Neoplas... Neoplasms, Abdo... Urogenital Neop... Genital Disease... Prostatic Disea... Antineoplastic ... Imatinib | STI571 (Glivec®... | 18 Years - | Novartis | |
| Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC | NCT01917279 | Breast Neoplasm... Neoplasms by Si... Neoplasm Metast... Breast Diseases Skin Diseases | Docetaxel plus ... Intermittent Ca... Metronomic Cape... | 18 Years - | ChineseAMS | |
| A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma | NCT00102609 | Soft Tissue Sar... Sarcoma Neoplasms, Conn... Neoplasms by Hi... Neoplasms | Doxorubicin Trabectedin Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | NCT05768139 | Breast Cancer Gynecologic Can... HNSCC Solid Tumors, A... | STX-478 Fulvestrant | 18 Years - | Scorpion Therapeutics, Inc. | |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | NCT04862780 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla... | BLU-945 osimertinib | 18 Years - | Blueprint Medicines Corporation | |
| A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies | NCT01273480 | Neoplasm Metast... | Sequence 1 Sequence 2 Sequence 1 Sequence 2 | 18 Years - | Janssen Research & Development, LLC | |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | NCT05592626 | Advanced Solid ... Genital Neoplas... Urogenital Neop... Lung Neoplasm Neoplasms by Si... Papillomavirus ... Epstein-Barr Vi... Carcinoma Neoplasms Vulvar Neoplasm... Vulvar Diseases Abdominal Neopl... | STAR0602 | 18 Years - | Marengo Therapeutics, Inc. | |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer | NCT03081858 | Bladder Cancer ... Non-Muscle Inva... Bladder Cancer Urinary Bladder Transitional Ce... Urinary Bladder... Urologic Neopla... Urogenital Neop... Urinary Bladder... Urologic Diseas... | TSD-001 | 18 Years - 85 Years | Lipac Oncology LLC | |
| Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors | NCT04669899 | Cancer | JTX-8064 pimivalimab | 18 Years - | Jounce Therapeutics, Inc. | |
| ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors | NCT01031212 | Tumors | ASA404 Cetuximab Carboplatin Paclitaxel | 18 Years - | University of California, San Francisco | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma | NCT01345357 | Solid Tumors or... | CEP-9722 Gemcitabine Cisplatin | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer | NCT03146663 | Ovarian Cancer | NUC-1031 500 mg NUC-1031 750mg | 18 Years - | NuCana plc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
